Brief: Enrollment Completed In The Feasibility Phase Of The Foresee Clinical Trial With Biocept’S Cnside Assay

Biocept

21/09/2023 13:18

Sept 21 (Reuters) - Biocept Inc  BIOC.O :
    * ENROLLMENT COMPLETED IN THE FEASIBILITY PHASE OF THE
FORESEE
CLINICAL TRIAL WITH BIOCEPT’S CNSIDE™ ASSAY TO EVALUATE PATIENTS
WITH LEPTOMENINGEAL METASTASES
    * BIOCEPT INC- BIOCEPT EXPECTS TO HAVE RESULTS FROM
FEASIBILITY
PHASE OF FORESEE TRIAL IN FIRST HALF OF 2024

Source text for Eikon:  ID:nBw8Kb4zqa 
Further company coverage:  BIOC.O 

 ((Reuters.Briefs@thomsonreuters.com))